Definitive Healthcare (NASDAQ:DH) Raised to "Buy" at Wall Street Zen

Definitive Healthcare (NASDAQ:DH - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Several other analysts have also recently weighed in on DH. Barclays lowered their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating on the stock in a research report on Monday, March 3rd. The Goldman Sachs Group raised their price target on Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research report on Monday, May 12th. Finally, BTIG Research lowered Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $5.10.

Definitive Healthcare Price Performance

NASDAQ:DH remained flat at $3.80 during trading hours on Friday. The company had a trading volume of 1,144,785 shares, compared to its average volume of 795,865. Definitive Healthcare has a 12 month low of $2.15 and a 12 month high of $6.16. The company has a 50 day moving average of $3.17 and a two-hundred day moving average of $3.69. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The company has a market cap of $564.83 million, a price-to-earnings ratio of -0.87, a P/E/G ratio of 6.61 and a beta of 1.58.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The company had revenue of $59.19 million during the quarter, compared to analyst estimates of $56.20 million. Definitive Healthcare had a positive return on equity of 3.69% and a negative net margin of 206.05%. Definitive Healthcare's revenue was down 6.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.08 earnings per share. On average, analysts expect that Definitive Healthcare will post 0.16 EPS for the current year.

Institutional Investors Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC lifted its position in Definitive Healthcare by 166.0% in the first quarter. Jane Street Group LLC now owns 105,114 shares of the company's stock valued at $304,000 after purchasing an additional 65,597 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Definitive Healthcare by 564.2% in the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock worth $25,191,000 after buying an additional 7,404,363 shares during the period. Petrus Trust Company LTA bought a new stake in Definitive Healthcare during the 1st quarter valued at $72,000. AQR Capital Management LLC boosted its position in Definitive Healthcare by 56.7% during the 1st quarter. AQR Capital Management LLC now owns 590,149 shares of the company's stock valued at $1,706,000 after buying an additional 213,562 shares during the period. Finally, PDT Partners LLC bought a new stake in Definitive Healthcare in the 1st quarter worth $152,000. Institutional investors own 98.67% of the company's stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.